SCHEMBL15034860

SCHEMBL15034860

Cc1ccccc1Oc1cc2cnc(Nc3ccc(N4CCN5CCCC5C4)cc3)nc2n(Cc2cccn2-c2ccncc2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 9/20 0.43
FGFR2 P21802 7/20 0.43
FGFR4 P22455 7/20 0.43
FGFR3 P22607 7/20 0.43
KDR P35968 2/20 0.43
MAPK8 P45983 2/20 0.42
CDK4 P11802 13/20 0.40
CCND1 P24385 12/20 0.40
CCNA2 P20248 6/20 0.40
CDK2 P24941 6/20 0.40
EGFR P00533 1/20 0.39
TNK2 Q07912 1/20 0.39
CDK6 Q00534 2/20 0.38
CCND2 P30279 3/20 0.38
CCND3 P30281 3/20 0.38
PIK3CD O00329 1/20 0.38
PRKAB2 O43741 1/20 0.38
NUAK1 O60285 1/20 0.38
CCNT1 O60563 1/20 0.38
ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15242113 0.93 MAPK8 (0.46) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15034993 0.86 FGFR1 (0.44) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15277149 0.81 MAPK8 (0.43) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15035850 0.80 FGFR1 (0.42) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15041773 0.79 MAPK8 (0.47) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15034887 0.77 MAPK8 (0.52) FGFR1FGFR2FGFR4FGFR3MAPK8
SCHEMBL15280218 0.77 MAPK8 (0.46) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15035392 0.77 CDK4 (0.47) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15034778 0.75 MAPK8 (0.52) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15035328 0.74 FGFR1 (0.45) FGFR1FGFR2FGFR4FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK5 FGFR1 2874/4885FGFR2 2557/4885FGFR4 2801/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 FGFR1 1919/4885FGFR2 1706/4885FGFR4 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.